Publication: Managed Care
. . . Treatment adherence was significantly better for the shorter regimen. Nearly all (97%) of those assigned to the short-course therapy completed the full antibiotic course, compared with 90% of participants in the nine-month arm.
“Compared with standard tuberculosis preventive therapy for people living with HIV, this short-course therapy is similarly safe and effective but reduces treatment time from nine months to one,” said Dr. Chaisson. “This ultra-short course therapy could become an important tool to control HIV-related tuberculosis and has the potential to transform global tuberculosis control efforts.” . . .
Access Full Article
Publication: MedPage Today
. . . At the press conference, Chaisson said that while prevention of TB with isoniazid is effective, "uptake has been appallingly bad." He added that the longer the course of the therapy is, the more people stop taking it, and described "a sense of futility" among clinicians about this problem.
A shorter, 4-week course of rifapentine and isoniazid had shown promise in animal studies, the authors said, so they hypothesized it would be non-inferior to the usual 9-month standard of care. "The bottom line is," Chaisson added, "it was." . . .
Access Full Article
. . . A previous trial showed the effectiveness of a 3-month regimen, said Richard Chaisson, MD, from Johns Hopkins University in Baltimore, Maryland . . .
Access full article
. . . Researchers followed 3000 people in 10 countries over 2 years who were living with HIV and also likely had latent TB, a bacterial infection that can be cleared with proper treatment. Instead of subjecting them all to a recommended prevention strategy—a 9-month course of the drug isoniazid—they treated half with the 9-month course and half with a monthlong combination of isoniazid and rifapentine . . .
Access Full Article
A5279 and P1078 are referenced in this press release from Johns Hopkins Medicine.
Access Full Press Release
Each year, World AIDS Day serves as time for important community outreach at the BJGMC Clinical Research Site. This year was no different.
On Friday, December 1, 150 people participated in a non-communicable diseases awareness camp for people living with HIV that was convened by the BJGMC-CRS Team at the Antiretroviral Therapy Center at Sassoon General Hospitals, Pune. Activities were led by Dr. Shashikala Sangle (Principal Investigator of TREAT Asia studies), Dr. Sandesh Patil (Clinical Coordinator at BJGMC-CRS), Mrs. Suhasini Surwase (TREAT Asia Counselor) and counselors Mrs. Archana Pawar and Mrs. Kanta Zarekar.
Discussions and activities were focused on the complications of having HIV and non-communicable disease, and the importance of identifying symptoms associated with non-communicable diseases and getting regular screenings to facilitate early diagnosis and prevent severe disease. Free blood sugar and blood pressure screenings were offered. Following biometric assessment, counselors spoke with attendees about the importance of maintaining a healthy lifestyle, including proper nutrition and exercise, while taking antiretroviral therapy. To incentivize healthy nutrition, attendees were provided with fruits at the end of their assessment.
The team developed a rolling presentation covering the essentials about non-communicable that was was played throughout the day. The BJGMC-CRS team would like to extend their gratitude to Dr. Sangle and all the ART center staff for helping to make this program successful!
Publication: Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent...
OPEN TO ACCRUAL
V1.0 of IMPAACT 2001, a PK study of rifapentine and isoniazid in pregnant and postpartum women, has opened to accrual.
Read more on ACTG Network
Publication: ACTG Network
Kevin Robertson, PhD, Investigator, University of North Carolina, Chapel Hill Clinical Research Site
A5303 was entitled “Systemic Inflammatory and Immune Biomarkers in Neurocognitive Changes with Initial ART” and was the largest randomized clinical trial studying neurocognitive outcomes ever conducted in the United States with over 200 treatment naïve participants who were followed after ART initiation for 48 weeks. Within the HIV research community, considerable interest in neurocognitive impairment in HIV as well as the desire to better understand the underlying pathogenesis of HIV-associated neurocognitive disorder (HAND). Biomarkers are an important way of looking at that pathogenesis to try to understand how HAND develops, and why it continues in some on effective antiretroviral therapy.
A5303 researchers found correlations between activated T cells and neurocognitive performance at baseline when viral loads are high, but these correlations were not there after the virus was suppressed with treatment. However, after the virus was suppressed, there were correlations between monocytes and neurocognitive impairment, not there at baseline. This finding fits some theories of which cells (monocytes) are driving HAND. These findings suggest that the driving mechanism behind HAND before ART and on ART may be different. In large part, A5303 confirmed that biomarkers in the periphery, (the blood) provided only weak correlations with neurocognitive impairment, and are likely too distant from the brain to be predictive. Biomarkers from Cerebrospinal Fluid (CSF) are likely more reflective of processes in the brain and central nervous system.
A5303 established that only a few biomarkers sampled in the blood were related to neurocognitive impairment. There is still a need to better understand the pathogenesis underlying continued neurocognitive impairment, and to continue looking for the causes to be able to better treat and prevent HAND.
Read more on ACTG Network
Publication: Huffington Post
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa. Read more on Huffington Post website
November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. David Hardy, Whitman-Walker Clincial Trials Site (Washington) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore) Non-voting Member, Antiretroviral Therapy Strategies Subcommittee. Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India) Investigator, Tuberculosis Transformative Science Group. Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, Tuberculosis Transformative Science Group. Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore) Chair, Site Management & Clinical Care Committee
- < 1 2 3 4 >